Interplay between the cancer genome and epigenome.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Individualized medicine from prewomb to tomb. Cell (2014) 2.76

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10

Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99

Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature (2014) 1.89

Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature (2014) 1.80

Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab (2014) 1.74

Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53

CBP binding outside of promoters and enhancers in Drosophila melanogaster. Epigenetics Chromatin (2015) 1.41

A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40

Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest (2014) 1.27

Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Med (2014) 1.23

MethylSig: a whole genome DNA methylation analysis pipeline. Bioinformatics (2014) 1.22

Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest (2014) 1.20

Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. Nat Commun (2014) 1.20

Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet (2014) 1.09

Epigenetic regulation by chromatin activation mark H3K4me3 in primate progenitor cells within adult neurogenic niche. Sci Rep (2014) 1.07

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07

Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res (2013) 1.07

Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife (2014) 1.06

BLUEPRINT: mapping human blood cell epigenomes. Haematologica (2013) 1.03

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia (2014) 1.03

Pan-cancer patterns of DNA methylation. Genome Med (2014) 1.02

The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. Genome Res (2015) 1.01

Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin (2015) 0.99

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia (2013) 0.96

Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet (2015) 0.95

Histone target selection within chromatin: an exemplary case of teamwork. Genes Dev (2014) 0.95

Heterogeneity of DNA methylation in multifocal prostate cancer. Virchows Arch (2014) 0.95

Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomarkers Prev (2015) 0.94

Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma. PLoS One (2013) 0.94

At the tipping point for epigenetic therapies in cancer. J Clin Invest (2014) 0.94

Minireview: transgenerational epigenetic inheritance: focus on endocrine disrupting compounds. Endocrinology (2014) 0.92

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell (2015) 0.91

Evolving understanding of the CLL genome. Semin Hematol (2014) 0.91

Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One (2014) 0.91

Impact of soy isoflavones on the epigenome in cancer prevention. Nutrients (2014) 0.90

Endoplasmic reticulum stress, genome damage, and cancer. Front Oncol (2015) 0.90

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget (2015) 0.90

Intratumoral Heterogeneity of the Epigenome. Cancer Cell (2016) 0.90

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood (2015) 0.89

Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res (2016) 0.88

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS One (2013) 0.88

Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88

DNA promoter methylation-dependent transcription of the double C2-like domain β (DOC2B) gene regulates tumor growth in human cervical cancer. J Biol Chem (2014) 0.87

An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol (2015) 0.87

Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood (2014) 0.87

Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med (2016) 0.87

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood (2015) 0.86

Structure and mutagenesis of the DNA modification-dependent restriction endonuclease AspBHI. Sci Rep (2014) 0.86

The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res (2013) 0.86

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. Front Oncol (2013) 0.86

The tissue is the issue: improved methylome analysis from paraffin-embedded tissues by application of the HOPE technique. Lab Invest (2014) 0.86

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget (2015) 0.85

Alterations of DNA methylome in human bladder cancer. Epigenetics (2013) 0.85

A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics Chromatin (2014) 0.85

Epigenetic therapy in lung cancer. Front Oncol (2013) 0.85

Cell surface-based sensing with metallic nanoparticles. Chem Soc Rev (2015) 0.85

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci U S A (2016) 0.84

Metabolism and epigenetics: a link cancer cells exploit. Curr Opin Biotechnol (2014) 0.84

DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. BMC Cancer (2014) 0.84

Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. J Am Soc Nephrol (2015) 0.84

Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res (2014) 0.84

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res (2016) 0.83

Cancer hallmarks sustained by ectopic activations of placenta/male germline genes. Cell Cycle (2013) 0.83

MYC is a critical target of FBXW7. Oncotarget (2015) 0.83

Genetic and Epigenetic Alterations in Bladder Cancer. Int Neurourol J (2016) 0.83

Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget (2015) 0.83

Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype. Epigenetics Chromatin (2015) 0.81

Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. Antioxid Redox Signal (2014) 0.81

Identification of key factors conquering developmental arrest of somatic cell cloned embryos by combining embryo biopsy and single-cell sequencing. Cell Discov (2016) 0.81

Insights into newly discovered marks and readers of epigenetic information. Nat Chem Biol (2016) 0.81

Characterising the epigenome as a key component of the fetal exposome in evaluating in utero exposures and childhood cancer risk. Mutagenesis (2015) 0.80

Systematically Prioritizing Functional Differentially Methylated Regions (fDMRs) by Integrating Multi-omics Data in Colorectal Cancer. Sci Rep (2015) 0.80

Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Res (2015) 0.80

Renal Cancer Stem Cells: Characterization and Targeted Therapies. Stem Cells Int (2016) 0.80

De novo deciphering three-dimensional chromatin interaction and topological domains by wavelet transformation of epigenetic profiles. Nucleic Acids Res (2016) 0.80

Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One (2014) 0.79

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget (2016) 0.79

Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics. Epigenetics (2014) 0.79

Early Prediction of Cancer Progression by Depth-Resolved Nanoscale Mapping of Nuclear Architecture from Unstained Tissue Specimens. Cancer Res (2015) 0.79

Identification of genes with consistent methylation levels across different human tissues. Sci Rep (2014) 0.79

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Res (2017) 0.79

JNK-dependent gene regulatory circuitry governs mesenchymal fate. EMBO J (2015) 0.78

Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget (2014) 0.78

The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.78

Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups. BMC Cancer (2015) 0.78

Cross-species Analyses Unravel the Complexity of H3K27me3 and H4K20me3 in the Context of Neural Stem Progenitor Cells. Neuroepigenetics (2016) 0.78

Endogenous retroviral promoter exaptation in human cancer. Mob DNA (2016) 0.78

Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers. Genes (Basel) (2015) 0.78

Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. PLoS One (2015) 0.78

Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer. RNA Biol (2014) 0.78

Inhibition of cellular methyltransferases promotes endothelial cell activation by suppressing glutathione peroxidase 1 protein expression. J Biol Chem (2014) 0.78

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. Oncoscience (2015) 0.77

New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci (2016) 0.77

Long noncoding RNAs in DNA methylation: new players stepping into the old game. Cell Biosci (2016) 0.77

Epigenetic States of nephron progenitors and epithelial differentiation. J Cell Biochem (2015) 0.77

Hallmarks of cancer: the next generation. Cell (2011) 140.01

An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73

A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Human DNA methylomes at base resolution show widespread epigenomic differences. Nature (2009) 34.27

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05

MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75

Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37

The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

Selective inhibition of BET bromodomains. Nature (2010) 18.79

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell (2007) 16.66

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29

DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30

ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07

CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02

Cancer epigenetics comes of age. Nat Genet (1999) 12.63

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34

The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44

A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33

Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet (2008) 11.17

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73

Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet (2006) 10.47

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66

Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47

Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28

Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87

5-Methylcytosine in eukaryotic DNA. Science (1981) 8.85

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45

The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34

Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96

IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95

Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74

Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell (2008) 7.68

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14

Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet (2011) 6.98

SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27

Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13

Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06

Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03

Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02

H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat Genet (2009) 5.82

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72

Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70

Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66

A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell (1985) 5.63

Determinants of nucleosome organization in primary human cells. Nature (2011) 5.50

Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28

Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell (2011) 5.27

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08

TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90

Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85

Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77

Epigenetic regulation by long noncoding RNAs. Science (2012) 4.74

The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature (2006) 4.74

Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res (1982) 4.61

Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60

Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet (2008) 4.44

DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49

Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70

Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84

Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68

Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97

Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79

Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61

DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One (2007) 3.30

Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Hum Mol Genet (2009) 2.85

Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38

Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res (2013) 2.19

Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12

Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04

DNA methylation as a biomarker for cardiovascular disease risk. PLoS One (2010) 2.04

Bis-SNP: combined DNA methylation and SNP calling for Bisulfite-seq data. Genome Biol (2012) 2.02

Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99

Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog (2010) 1.94

A comparison of cluster analysis methods using DNA methylation data. Bioinformatics (2004) 1.94

Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One (2009) 1.90

DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75

Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res (2002) 1.73

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73

The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell (2013) 1.68

DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65

Sensitive detection of DNA methylation. Ann N Y Acad Sci (2003) 1.65

Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59

Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology (2007) 1.56

Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS One (2007) 1.55

Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res (2006) 1.52

Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells (2010) 1.50

Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47

Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum Genet (2012) 1.47

Discovery of multi-dimensional modules by integrative analysis of cancer genomic data. Nucleic Acids Res (2012) 1.46

MethyLight. Methods Mol Biol (2009) 1.45

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44

DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42

An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst (2013) 1.42

Distinct methylation profiles of glioma subtypes. Int J Cancer (2003) 1.38

Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev (2002) 1.38

Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Res (2008) 1.36

Sex differential in methylation patterns of selected genes in Singapore Chinese. Hum Genet (2005) 1.35

DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest (2007) 1.34

Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation (2002) 1.32

Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol (2006) 1.29

Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer (2008) 1.24

Combined bisulfite restriction analysis (COBRA). Methods Mol Biol (2002) 1.20

Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet (2002) 1.19

DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol (2002) 1.18

Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res (2004) 1.17

Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One (2012) 1.14

The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int J Cancer (2009) 1.14

Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer (2007) 1.14

DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer (2007) 1.11

Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10

The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers (2007) 1.09

The mutagenic potential of duodenoesophageal reflux. Ann Surg (2005) 1.08

Rapid and quantitative method of allele-specific DNA methylation analysis. Biotechniques (2006) 1.08

Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer (2005) 1.06

Mild depletion of dietary folate combined with other B vitamins alters multiple components of the Wnt pathway in mouse colon. J Nutr (2007) 1.04

DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol Biomarkers Prev (2009) 1.04

Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn (2010) 1.04

Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study. Nutr Cancer (2012) 1.03

Gene-specific methylation and subsequent risk of colorectal adenomas among participants of the polyp prevention trial. Cancer Epidemiol Biomarkers Prev (2005) 1.01

Analysis of complex methylation data. Methods (2002) 1.00

Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia (2010) 0.99

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology (2013) 0.98

Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer. PLoS One (2010) 0.95

Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut (2011) 0.94

In epigenetic therapy, less is more. Cell Stem Cell (2012) 0.93

Hormone therapy, DNA methylation and colon cancer. Carcinogenesis (2010) 0.91

Diet, cancer and aging in DNA mismatch repair deficient mice. Carcinogenesis (2002) 0.89

Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer (2004) 0.89

Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women. Cancer Prev Res (Phila) (2011) 0.88

Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2007) 0.88

Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. Cancer Prev Res (Phila) (2011) 0.88

Locking in on the human methylome. Nat Biotechnol (2009) 0.88

Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics (2013) 0.88

Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenetics Chromatin (2013) 0.88

2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett (2008) 0.88

Altered folate availability modifies the molecular environment of the human colorectum: implications for colorectal carcinogenesis. Cancer Prev Res (Phila) (2011) 0.87

Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One (2011) 0.87

A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res (2012) 0.87

Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol (2015) 0.84

Epigenetic subgroups of esophageal and gastric adenocarcinoma with differential GATA5 DNA methylation associated with clinical and lifestyle factors. PLoS One (2011) 0.80

Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice. Carcinogenesis (2011) 0.80

Cluster analysis for DNA methylation profiles having a detection threshold. BMC Bioinformatics (2006) 0.80

Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol (2005) 0.79